OPTUS Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
OPTUS Pharmaceutical's earnings have been declining at an average annual rate of -12.3%, while the Medical Equipment industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 4.2% per year. OPTUS Pharmaceutical's return on equity is 7.4%, and it has net margins of 13.2%.
Key information
-12.3%
Earnings growth rate
-10.7%
EPS growth rate
| Medical Equipment Industry Growth | 22.7% |
| Revenue growth rate | 4.2% |
| Return on equity | 7.4% |
| Net Margin | 13.2% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
OPTUS Pharmaceutical's (KOSDAQ:131030) Earnings Are Of Questionable Quality
Mar 13
DHP Korea's (KOSDAQ:131030) Problems Go Beyond Weak Profit
Mar 09Recent updates
Benign Growth For OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030) Underpins Stock's 25% Plummet
Nov 14Investors Could Be Concerned With OPTUS Pharmaceutical's (KOSDAQ:131030) Returns On Capital
Nov 13Capital Allocation Trends At OPTUS Pharmaceutical (KOSDAQ:131030) Aren't Ideal
Aug 07There's Reason For Concern Over OPTUS Pharmaceutical Co., Ltd.'s (KOSDAQ:131030) Massive 28% Price Jump
Jun 27There's No Escaping OPTUS Pharmaceutical Co., Ltd.'s (KOSDAQ:131030) Muted Earnings Despite A 43% Share Price Rise
Mar 25OPTUS Pharmaceutical's (KOSDAQ:131030) Earnings Are Of Questionable Quality
Mar 13The Returns On Capital At DHP Korea (KOSDAQ:131030) Don't Inspire Confidence
Apr 05DHP Korea's (KOSDAQ:131030) Problems Go Beyond Weak Profit
Mar 09DHP Korea Co., Ltd.'s (KOSDAQ:131030) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 10
How Much Did DHP Korea's(KOSDAQ:131030) Shareholders Earn From Share Price Movements Over The Last Five Years?
Jan 12Should We Be Excited About The Trends Of Returns At DHP Korea (KOSDAQ:131030)?
Dec 08Revenue & Expenses Breakdown
How OPTUS Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 77,791 | 10,248 | 31,709 | 1,783 |
| 31 Mar 24 | 74,206 | 11,114 | 30,752 | 1,434 |
| 31 Dec 23 | 72,426 | 10,760 | 30,619 | 1,384 |
| 30 Sep 23 | 67,100 | 8,004 | 28,769 | 1,326 |
| 30 Jun 23 | 63,352 | 7,557 | 27,001 | 1,272 |
| 31 Mar 23 | 60,865 | 4,845 | 25,936 | 1,192 |
| 31 Dec 22 | 58,658 | 5,012 | 24,147 | 1,343 |
| 30 Sep 22 | 57,723 | 8,119 | 22,356 | 1,627 |
| 30 Jun 22 | 57,819 | 9,130 | 21,547 | 1,529 |
| 31 Mar 22 | 57,606 | 10,242 | 20,597 | 1,376 |
| 31 Dec 21 | 57,316 | 9,892 | 20,496 | 1,110 |
| 30 Sep 21 | 54,719 | 9,358 | 19,970 | 742 |
| 30 Jun 21 | 56,109 | 8,942 | 21,448 | 700 |
| 31 Mar 21 | 59,409 | 12,055 | 22,489 | 707 |
| 31 Dec 20 | 60,827 | 14,405 | 22,288 | 822 |
| 30 Sep 20 | 66,327 | 14,770 | 23,446 | 1,302 |
| 30 Jun 20 | 64,733 | 16,123 | 21,989 | 1,327 |
| 31 Mar 20 | 61,917 | 15,338 | 20,741 | 1,289 |
| 31 Dec 19 | 60,441 | 14,596 | 20,247 | 1,148 |
| 30 Sep 19 | 55,404 | 12,178 | 18,967 | 632 |
| 30 Jun 19 | 53,579 | 11,441 | 17,786 | 560 |
| 31 Mar 19 | 51,389 | 10,526 | 16,511 | 694 |
| 31 Dec 18 | 49,625 | 10,003 | 15,436 | 758 |
| 30 Sep 18 | 49,778 | 10,549 | 14,743 | 802 |
| 30 Jun 18 | 50,484 | 11,423 | 14,658 | 819 |
| 31 Mar 18 | 49,914 | 12,120 | 14,415 | 677 |
| 31 Dec 17 | 49,808 | 12,879 | 14,284 | 552 |
| 30 Sep 17 | 50,312 | 14,455 | 14,046 | 584 |
| 30 Jun 17 | 48,760 | 13,582 | 13,345 | 884 |
| 31 Mar 17 | 47,351 | 12,787 | 12,867 | 1,097 |
| 31 Dec 16 | 44,720 | 11,496 | 12,379 | 1,248 |
| 30 Sep 16 | 42,229 | 10,723 | 12,187 | 1,552 |
| 30 Jun 16 | 41,558 | 10,854 | 11,658 | 2,095 |
| 31 Mar 16 | 40,258 | 10,499 | 11,175 | 2,230 |
| 31 Dec 15 | 38,559 | 10,298 | 10,746 | 2,024 |
| 30 Sep 15 | 38,020 | 10,674 | 10,477 | 1,476 |
| 30 Jun 15 | 35,466 | 10,160 | 10,401 | 519 |
| 31 Mar 15 | 33,769 | 9,800 | 10,309 | 95 |
| 31 Dec 14 | 32,566 | 9,519 | 10,111 | 88 |
| 30 Sep 14 | 37,206 | 5,353 | 11,516 | 81 |
| 30 Jun 14 | 28,662 | 2,832 | 8,951 | 76 |
| 31 Mar 14 | 27,685 | 2,136 | 8,570 | 74 |
| 31 Dec 13 | 26,850 | 1,425 | 8,050 | 69 |
Quality Earnings: A131030 has high quality earnings.
Growing Profit Margin: A131030's current net profit margins (13.2%) are higher than last year (11.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A131030's earnings have declined by 12.3% per year over the past 5 years.
Accelerating Growth: A131030's earnings growth over the past year (35.6%) exceeds its 5-year average (-12.3% per year).
Earnings vs Industry: A131030 earnings growth over the past year (35.6%) exceeded the Medical Equipment industry 1.6%.
Return on Equity
High ROE: A131030's Return on Equity (7.4%) is considered low.